Prednisone therapy and pharmacokinetic
ApprovedSmall molecule
Prednisone therapy and pharmacokinetic is one of 22 small molecule programs targeting Giant Cell Arteritis. It is currently in Approved.
1
Indications
1
Total Trials
0
Active Trials
21
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
30 competitors in Giant Cell Arteritis
#DrugCompanyPhaseTrials
1Cosentyx
NovartisPhase 3
Orencia
Bristol-Myers SquibbPhase 3
Rinvoq
AbbViePhase 3
Rayos
RRoxane Laboratories
Phase 3
Humira
CCelltrion
Phase 3
Kineret
SSwedish Orphan Biovitrum
Phase 3
Sirukumab
Johnson & JohnsonPhase 3
Treatment
GSKPhase 3
Trexall
Alnylam PharmaceuticalsPhase 2
Tremfya
Johnson & JohnsonPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- UUniversity Hospital, Caen